A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis

Cohen, S, Emery, P, Greenwald, M et al. (8 more authors) (2016) A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis. British Journal of Clinical Pharmacology, 82 (1). pp. 129-138. ISSN 0306-5251

Abstract

Metadata

Authors/Creators:
  • Cohen, S
  • Emery, P
  • Greenwald, M
  • Yin, D
  • Becker, J-C
  • Melia, LA
  • Li, R
  • Gumbiner, B
  • Thomas, D
  • Spencer-Green, G
  • Meng, X
Copyright, Publisher and Additional Information: (c) 2016, Pfizer Inc. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmocological Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License [https://creativecommons.org/licenses/by-nc-nd/4.0/], which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
Keywords: biosimilar; CD19+ B cell counts; immunogenicity; pharmacokinetics; rituximab; safety
Dates:
  • Accepted: 18 February 2016
  • Published (online): 29 April 2016
  • Published: July 2016
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 10 Aug 2018 11:25
Last Modified: 10 Aug 2018 11:25
Status: Published
Publisher: Wiley
Identification Number: https://doi.org/10.1111/bcp.12916
Related URLs:

Download

Filename: P994.pdf

Licence: CC-BY-NC-ND 4.0

Share / Export

Statistics